Biogenerics: The bad arguments just won’t stop

Biogenerics: The bad arguments just won’t stop

It’s always fascinating to see just how entitled biotechnology investors feel about the outsized rewards the industry bestows whenever one of their long-shot companies finally strikes it rich — not to mention how thoroughly that sense of entitlement seems to muddle their thinking.

Case in… Continue Reading

Biotech’s double standard on biogenerics

Biotech’s double standard on biogenerics

(UPDATED: See below.)

Yesterday, the WSJ Health Blog cited a WSJ story as evidence that “biogenerics” — that is, generic versions of biotech drugs, which currently don’t exist — need to be treated with caution. Unfortunately, that post missed a much more important point about biogenerics: The… Continue Reading